Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have previously received Pell's lentiviral-based gene-edited immune cell treatment, either on its own or combined with other treatments, as part of a clinical trial.
- People whose last dose of this gene-edited immune cell treatment was received within the past 15 years.
- People (or their parent or legal guardian, if applicable) who are able to read, understand, and sign a consent form agreeing to the study's requirements.
Who may not be able to join:
- There are no specific exclusion criteria listed for this trial — the trial site will be able to confirm whether a person meets the requirements.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Chen-Lung Lin, MD, Pell Bio-Med Technology Co., Ltd.
Phone: 886-2-8791-1789
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To assess delayed adverse events which are suspected related to previous gene-edited immune cell therapy
Can't join this trial?
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.